Our mission: To develop safer and more effective immunotherapies through innovations in drug delivery.
Avidea Technologies is a leader in the development of polymer-based drug delivery systems with immunotherapeutic applications.
Our technology and team are building on more than two decades of pioneering work by our world-class scientific founders and advisors from the National Institutes of Health, the University of Oxford and the Institute for Macromolecular Chemistry. Our founders, advisors and collaborators are experts in the fields of immunology, oncology, vaccines and drug-delivery.
We apply the interdisciplinary expertise of our team to overcome key challenges in drug delivery and advance promising immunotherapies to patients in need.
Location: United States, Maryland, Baltimore
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | BioHealth ... | biohealthi... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 08.09.2022 | 3 takeaways from Johns Hopkins Technology Ventures’ annual r... | Johns Hopkins University is offering a by-the-numbers look into its entrepreneurship ecosystem with ... | technical.... |
| 16.12.2021 | Johns Hopkins spinout Avidea was acquired by UK company Vacc... | UK biopharmaceutical company Vaccitech has acquired Johns Hopkins spinout Avidea Technologies in a d... | technical.... |
| 14.06.2021 | Avidea's SNAPvax™ Tolerance Vaccine Program Boosted by SAB A... | BALTIMORE, June 14, 2021 /PRNewswire/ -- Avidea Technologies, Inc. ("Avidea"), a biotechno... | marketscre... |
| 01.10.2018 | These 6 startups will pitch at Beta City 2018 | Beta City returns to City Garage in Port Covington on Thursday, October 4, for a celebration of the ... | technical.... |